The Latest Breaking News from MRUS

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.

Benzinga · Sep 29, 2025

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading.

Benzinga · Sep 29, 2025

Needham Says Merus' ASCO Update On Zeno 'Positive'

Needham writes that Merus NV (NASDAQ: MRUS) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer. 

Benzinga · Jun 6, 2022